Canaccord lowered the firm’s price target on AtriCure (ATRC) to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company’s Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: